Business
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":"\nConference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time\n\n\n\nAcute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025\n\n\n\nPreeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025\n\n\n\nCompleted $12 Million Private Placement, Extending Cash Runway Into Q3 2026\n\n\n\n MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, August 8, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 2024 financial results.\n\n\nReMEDy2 Phase 2/3 AIS Clinical Developments\n\n\nProgress continues with site activation activities accelerating. As part of this, DiaMedica has selected and prioritized fifteen research centers in the United States that are anticipated to be top enrollment centers. DiaMedica anticipates these top fifteen centers will enroll a disproportionately large share of participants in the study, and at least nine of these centers are expected to be activated this quarter.\n\n\nWith the recent acceleration in site activities the Company reiterates its guidance that full enrollment for the 144 patients for the interim analysis will be completed in the first quarter of 2025.\n\n\n\"Our clinical team is energized by the progress made over the past 90 days and is eager to activate and better support our high-volume centers,\" stated Dr. Lorianne Masuoka, DiaMedica’s Chief Medical Officer. \"We are also pleased to report that there have been no cases of hypotension in newly enrolled participants.\"\n\n\nPreeclampsia Program\n\n\nIn June 2024, the Company announced the expansion of the Company’s DM199 clinical development program into preeclampsia (PE). PE is a serious pregnancy disorder that typically develops after the 20th week of gestation, characterized by high blood pressure and damage to organ systems, often the kidneys and liver. Affecting up to 8% of pregnancies worldwide, preeclampsia can pose significant risks to both the mother and baby, including risk of st...